Clinical Trial Update: A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) [Phase 3]

View source ↗

Summary

The REMESLE-2 Phase 3 trial of telitacicept for moderately to severely active systemic lupus erythematosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Telitacicept

Snippet

Sponsor: Vor Biopharma | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: WITHDRAWN